Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Paladin labs has introduced Abstral (fentanyl citrate sublingual tablet) for the management of breakthrough pain in cancer patients who are already receiving, and tolerant to opioid analgesics for their underlying persistent cancer pain in Canada.
Subscribe to our email newsletter
Earlier in December 2008, ProStrakan Group, a wholly owned subsidiary of Kyowa Hakko Kirin, has licensed Canadian rights for Abstral to Paladin.
Paladin Labs president and CEO Jonathan Ross Goodman said though officially launching today, Abstral has been available to patients and their physicians in Canada for almost 2 months under the compassionate early use program.
"This early experience program with Abstral has seen meaningful and heart-warming quality of life improvements in many patients taking our product," Goodman said.